The hook
Can a real-world olive oil, not a capsule, nudge glucose control, inflammation, and the microbiome at the same time? That sounds like a nutrition headline, but here the answer is actually more nuanced. The study is small and uncontrolled, yet the pattern is coherent enough to matter. If you care about whether EVOO does anything beyond replacing another fat, this paper is interesting because it tracks three biologically linked outputs at once: HbA1c, IL-1β, and microbiota composition.
The result is not a miracle. It is a directional human signal from a polyphenol-rich Portuguese oil that appears to behave like a food, not a drug. That is exactly why it is worth paying attention to.
At a glance
- Journal: Biomolecules
- Authors: Correia et al.
- Year: 2025
- Design: Pre-post human intervention
- Participants: 37 enrolled, 33 paired clinical data
- Microbiome subset: 17 saliva samples
Study Overview
Key findings, with the actual numbers
The serum numbers are straightforward. In the 33-person paired dataset, HbA1c dropped from 5.12 ± 0.32% to 4.93 ± 0.24%, which the paper reports as p = 0.000. LDL-C also fell from 92.63 ± 24.53 to 83.23 ± 27.63 mg/dL, p = 0.024. Total cholesterol moved from 168.22 ± 30.93 to 162.79 ± 32.30 mg/dL, but that was not significant, and CRP fell from 0.65 ± 1.37 to 0.36 ± 0.20 mg/dL without reaching significance (p = 0.119).
That mix matters. This was not a broad metabolic collapse in every direction, and it was not just placebo noise either. The HbA1c and LDL-C changes are small in absolute terms, but they are biologically consistent with a better dietary fat pattern and a more phenol-rich oil matrix.
The inflammatory readout is where the paper gets more interesting. Salivary IL-1β fell by 87.14 pg/mL, while TNF-α, IFN-γ, and IL-4 did not move. That suggests a selective inflammatory shift rather than a blanket suppression of every cytokine. Selective is often what real nutrition effects look like.
The microbiome data are probably the most visually compelling. Stool Bacteroidota increased strongly, and in saliva, both Bacteroidota and Bacillota increased. The saliva subset was only 17 people, so I would not overcall the ecological meaning, but the direction matches the idea that EVOO polyphenols can act as a prebiotic substrate or at least a microbiota modulator.
Mechanism: why this makes biological sense
Polyphenols survive the food matrix
This oil was rich in hydroxytyrosol, oleuropein, tyrosol, and related phenolics. That matters because olive phenols are not just ornaments on a label, they can affect redox biology, endothelial signaling, and microbial fermentation once they reach the gut.
Less inflammatory signaling
IL-1β is a sensible target because it sits upstream in inflammatory cascades. If olive phenolics blunt NF-κB-related signaling or oxidative stress, a drop in IL-1β is exactly the kind of biomarker you would expect to see before harder outcomes move.
Microbiome mediation
EVOO polyphenols can be metabolized by microbes and may also favor taxa associated with better metabolic health. The Bacteroidota shift is not proof of benefit, but it fits the broader prebiotic hypothesis nicely.
Context: how this fits with prior olive-oil research
The best olive-oil trials usually show a pattern, not a miracle. Polyphenol-rich EVOO tends to look stronger than refined olive oil on oxidative stress, lipids, and some inflammatory markers. PREDIMED made the broader cardiovascular case. Smaller trials like this one try to explain why the signal exists in the first place.
What is new here is the dual readout from serum and microbiota. The authors are not just saying, “EVOO is healthy.” They are showing a plausible chain: a phenol-rich oil, taken daily, coincides with small but measurable shifts in glycemia, LDL-C, IL-1β, and bacterial composition. That is more mechanistic than a typical food intervention paper.
Still, the study stops short of proving causality. Without a control group, you cannot completely separate the oil from regression to the mean, seasonal drift, or subtle behavior changes over 100 days. So the paper confirms the olive-oil story, but it does not settle it.
Practical takeaway
- • If you use olive oil, using a genuinely polyphenol-rich extra virgin oil is likely more meaningful than just using any fat labeled “olive.”
- • If your goal is glucose control or inflammation, EVOO should be part of a pattern, not a standalone fix.
- • For shoppers, the most practical heuristic is still simple: true extra virgin, recent harvest, dark bottle, and ideally some chemistry data.
- • For clinicians, this is hypothesis-generating, not a replacement for standard diabetes or dyslipidemia management.
Limitations
No control group
This is the biggest problem. A before-after design is useful for signal detection, not for causal certainty.
Small sample
Only 33 paired clinical records and 17 saliva microbiome samples mean the estimates are fragile.
Single product, single region
The oil was a specific northern Portuguese EVOO, so generalizing to all EVOO is risky.
Self-reported diet
PREDIMED, IPAQ, and 3-day logs help, but they do not fully eliminate confounding.
Our take
I like this paper because it tries to connect chemistry with biology instead of just waving at “Mediterranean diet” as a magic phrase. The intervention dose was realistic, the oil chemistry was described, and the authors looked beyond lipids into inflammation and the microbiome.
I do not like the lack of a control arm, because it makes every positive result softer than it looks. But even with that caveat, the pattern is coherent enough to be useful. It suggests that a polyphenol-rich EVOO can do more than add monounsaturated fat. It may also tug on glycemia, inflammatory tone, and microbial ecology.
So the honest conclusion is this: promising, not definitive. But definitely not boring.
References
1. Correia M, et al. Unraveling the Extra Virgin Olive Oil Effect on Inflammation and on Gut and Saliva Microbiota. Biomolecules. 2025;15(3):338. doi:10.3390/biom15030338. PMID: 40149874. PubMed →
2. Correia M, et al. The Metabolic and Analytical Changes of Healthy Volunteers upon Intake of Portuguese Extra Virgin Olive Oil: A Comparison Study between Pre- and Post-Intervention. Nutrients. 2023;15:3351.
3. The trial registry for the parent study: NCT05852275.
Bottom line
A polyphenol-rich Portuguese EVOO showed real human biomarker shifts, especially HbA1c, IL-1β, and microbiome composition, but the study is still observational enough that it should be read as a strong clue, not a final answer.
See all research →